Susquehanna Fundamental Investments LLC Makes New Investment in Boston Scientific Co. (NYSE:BSX)

Susquehanna Fundamental Investments LLC acquired a new position in shares of Boston Scientific Co. (NYSE:BSX) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 29,518 shares of the medical equipment provider’s stock, valued at approximately $2,273,000.

Several other institutional investors have also modified their holdings of the company. CVA Family Office LLC lifted its position in shares of Boston Scientific by 7.4% during the 2nd quarter. CVA Family Office LLC now owns 1,909 shares of the medical equipment provider’s stock worth $147,000 after purchasing an additional 131 shares during the last quarter. International Assets Investment Management LLC lifted its position in shares of Boston Scientific by 0.6% during the 2nd quarter. International Assets Investment Management LLC now owns 22,596 shares of the medical equipment provider’s stock worth $1,740,000 after purchasing an additional 139 shares during the last quarter. ST Germain D J Co. Inc. lifted its position in shares of Boston Scientific by 8.0% during the 2nd quarter. ST Germain D J Co. Inc. now owns 1,923 shares of the medical equipment provider’s stock worth $148,000 after purchasing an additional 143 shares during the last quarter. Pinnacle Associates Ltd. lifted its position in shares of Boston Scientific by 2.0% during the 1st quarter. Pinnacle Associates Ltd. now owns 7,478 shares of the medical equipment provider’s stock worth $512,000 after purchasing an additional 148 shares during the last quarter. Finally, Transcend Capital Advisors LLC lifted its position in shares of Boston Scientific by 2.2% during the 2nd quarter. Transcend Capital Advisors LLC now owns 6,773 shares of the medical equipment provider’s stock worth $522,000 after purchasing an additional 148 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $74.12, for a total transaction of $517,579.96. Following the transaction, the executive vice president now directly owns 40,188 shares in the company, valued at $2,978,734.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BSX. BTIG Research boosted their price target on shares of Boston Scientific from $80.00 to $84.00 and gave the company a “buy” rating in a research report on Monday, July 15th. StockNews.com cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Citigroup boosted their price target on shares of Boston Scientific from $90.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price target on shares of Boston Scientific in a research report on Thursday, July 25th. Finally, Needham & Company LLC boosted their price target on shares of Boston Scientific from $82.00 to $86.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Three investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.65.

Boston Scientific Trading Up 0.5 %

Shares of Boston Scientific stock opened at $83.80 on Tuesday. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $84.89. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. The company’s 50-day simple moving average is $79.44 and its 200-day simple moving average is $75.43. The firm has a market cap of $122.94 billion, a price-to-earnings ratio of 70.42, a price-to-earnings-growth ratio of 2.78 and a beta of 0.79.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The business had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.02 billion. During the same period in the previous year, the business posted $0.53 earnings per share. The business’s revenue was up 14.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.